Biobank For MS And Other Demyelinating Diseases
Large-scale, Multi-disciplinary Sample and Data Repository for Multiple Sclerosis and Related Demyelinating Diseases
1 other identifier
observational
3,226
1 country
10
Brief Summary
To establish a large, longitudinal collection of high quality samples and data from subjects with MS, selected other demyelinating diseases (Transverse Myelitis (TM), Neuromyelitis Optica (NMO) or Devic's, Acute Disseminated Encephalomyelitis (ADEM), and Optic Neuritis (ON)), and related and unrelated unaffected controls. Samples and data will be available as a shared resource to scientists researching the causes, sub-types, and biomarkers of MS and related demyelinating diseases.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2006
Longer than P75 for all trials
10 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2006
CompletedFirst Submitted
Initial submission to the registry
March 8, 2007
CompletedFirst Posted
Study publicly available on registry
March 9, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
October 1, 2036
October 2, 2025
September 1, 2025
24.4 years
March 8, 2007
September 29, 2025
Conditions
Keywords
Study Arms (2)
Case
Control
Eligibility Criteria
Subjects with MS, selected other demyelinating diseases (Transverse Myelitis (TM), Neuromyelitis Optica (NMO) or Devic's, Acute Disseminated Encephalomyelitis (ADEM), and Optic Neuritis (ON)), and related and unrelated unaffected controls.
You may qualify if:
- age 18+ able to give informed consent or individuals younger than 18 with parental permission and able to give assent
- willing to provide up to 110 ml (50 ml for \< 18 years old) of blood via venipuncture
- experienced at least one CNS demyelinating event characteristic of MS, TM, NMO, ADEM, or ON
You may not qualify if:
- history of blood borne pathogens
- allogeneic bone marrow transplant
- clinical or radiological evidence of stroke, meningitis, or other well characterized diseases of the nervous system (with the exception of MS, TM, NMO, ADEM, or ON).
- weight less than 37 pounds
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (10)
Barrow Neurological Institute
Phoenix, Arizona, 85013, United States
Stanford University
Stanford, California, 94305, United States
The Rocky Mountain MS Center at Anschutz Medical Campus at UC Denver
Aurora, Colorado, 80045, United States
Shepherd Center
Atlanta, Georgia, 30309, United States
Johns Hopkins
Baltimore, Maryland, 21287, United States
Beth Israel Deaconess
Boston, Massachusetts, 02215, United States
University of Massachusetts Medical School
Worcester, Massachusetts, 01605, United States
Multiple Sclerosis Research Center of New York
New York, New York, 10019, United States
The Ohio State University
Columbus, Ohio, 43210, United States
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas, 76051, United States
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Benjamin Greenberg, M.D., M.H.S.
University of Texas
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 8, 2007
First Posted
March 9, 2007
Study Start
May 1, 2006
Primary Completion (Estimated)
October 1, 2030
Study Completion (Estimated)
October 1, 2036
Last Updated
October 2, 2025
Record last verified: 2025-09